Previous Article | Next Article 
Journal of Virology, June 1999, p. 4696-4704, Vol. 73, No. 6
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Proline Residues in Human Immunodeficiency Virus Type 1 p6Gag Exert a Cell Type-Dependent Effect on Viral
Replication and Virion Incorporation of Pol Proteins
Markus
Dettenhofer and
Xiao-Fang
Yu*
Department of Molecular Microbiology and
Immunology, Johns Hopkins University School of Hygiene and Public
Health, Baltimore, Maryland 21205
Received 20 October 1998/Accepted 13 February 1999
 |
ABSTRACT |
The C terminus of the HIV-1 Gag protein contains a proline-rich
domain termed p6Gag. This domain has been shown to play a
role in efficient virus release and incorporation of Vpr into virions.
In a previous study (X. F. Yu, L. Dawson, C. J. Tian, C. Flexner, and M. Dettenhofer, J. Virol. 72:3412-3417, 1998), we
observed that the removal of the p6 domain of Gag as well as drastic
mutations in the PTAP motif resulted in reduced virion-associated Pol
proteins from transfected COS cells. In the present study, amino acid
substitutions at residues 5 and 7 of p6Gag resulted in a
cell type-dependent replication of the mutant virus in CD4+
T cells; the virus was replication competent in Jurkat cells but
restricted in H9 cells and primary blood-derived monocytes. Established
Jurkat and H9 cell lines expressing p6Gag mutant and
parental virus were used to further understand this defect. Mutant
virions produced from H9 cells, which displayed no defect in
extracellular virion production, showed an ~16-fold reduction in Pol
protein levels, whereas the levels of Pol proteins were only marginally
reduced in mutant virions produced from Jurkat cells. The reduction in
the virion-associated Pol proteins could not be accounted for by
differences in the levels of intracellular p160Gag-Pol or
in the interaction between p55Gag and
p160Gag-Pol precursors. Electron microscopic analysis of
the p6Gag mutant virions showed a predominately immature
morphology in the absence of significant defects in Gag proteolytic
cleavage. Taken together, these data suggest that the proline-rich
motif of p6Gag is involved in the late stages of virus
maturation, which include the packaging of cleaved Pol proteins in
viral particles, a process which may involve cell-type-specific factors.
 |
INTRODUCTION |
Common to all retroviruses are three
major structural proteins, Gag, Pol, and Env (38). In human
immunodeficiency virus type 1 (HIV-1), Gag is expressed in the form of
a 55-kDa precursor, p55Gag, which is posttranslationally
cleaved into p17MA, p24CA, p7NC, and p6Gag by the viral
protease during virus assembly and maturation (38). The Pol
proteins of HIV-1 (protease, reverse transcriptase (RT), and integrase)
are synthesized in the form of a fusion protein that includes part of
the Gag protein (MA, CA, and NC, but not p6Gag). The
Gag-Pol fusion protein is the result of a
1 ribosomal frameshifting
event between the p7NC and p6Gag domains of Gag which
occurs with a frequency of 5 to 10% of the total Gag proteins
synthesized (38). Incorporation of these Pol proteins into
virions is believed to occur through the shared Gag regions of the
p55Gag and p160Gag-Pol precursors (21,
36).
The expression of retroviral Gag proteins, which constitute the
principal structural components of the virus, is sufficient to drive
viral particle assembly and budding (38). The domains that
constitute the Gag molecule play different roles in the ability of the
budding particle to emerge from the plasma membrane of an infected
cell. Mutagenesis studies have shown that the addition of a myristic
acid at the N terminus of HIV-1 Gag (5, 18), as well as
basic residues within the N terminus of the MA domain (44,
46), is critical for the accumulation of p55Gag at
the plasma membrane, the site of virus budding. MA also plays another
role during virus assembly, that of incorporating the viral envelope
glycoproteins into the surfaces of virions (9, 12, 40) by
interacting with the cytoplasmic tail of gp41 (6, 10, 12,
41).
The formation of virus particles involves the multimerization of
p55Gag through protein-protein interactions
(38). This process is controlled at least in part by the I
domain in NC (3, 8, 34, 45). Positively charged amino acids
in HIV-1 NC seem to be important for the function of the I domain
(4, 8). In addition, regions in MA that are important for
trimer formation (19, 28) and regions in CA that are
involved in dimer formation (7, 11a, 13, 27, 29, 37) are
also thought to play important roles in HIV-1 assembly. The p7NC domain
also contributes to the incorporation of the viral genomic RNA into the
virions (38).
In addition to the protein domains described above, retroviral
Gag molecules also encode regions which have been termed late-assembly (L) domains. Mutational analysis has suggested that these domains are involved in the late stage of virus particle formation, possibly controlling the efficient release of particles from the cell surface (17, 20, 30, 32, 35, 39, 43). Motifs of the L domains in
HIV-1 p6Gag (PTAPP), equine infectious anemia virus
p9Gag (YXXL), and Rous sarcoma virus p2 (PPPPY) have been
shown to be functionally interchangeable with regard to their effects
on particle release (30). The L domain of Rous sarcoma virus
p2 has also been shown to interact with WW protein binding motifs; however, the comparable domains in HIV-1 and equine infectious anemia
virus fail to bind this motif (16).
In addition to its involvement in particle release, HIV-1
p6Gag is also critical for the incorporation of Vpr into
particles (23, 25, 31). Mutagenesis studies have shown that
the C-terminal (LXX)4 repeat in p6Gag is
important for Vpr virion incorporation (25). This
conclusion is supported by the incorporation of Vpr into heterologous
virions when p6Gag is fused to the C terminus of the murine
leukemia virus Gag protein (23). More recently, a role for
HIV-1 p6Gag in the control of particle size has been
reported (15).
Regions in p24CA have been implicated in the association of
p55Gag and p160Gag-Pol prior to viral
protease-directed cleavage of these molecules (21, 36).
These may constitute some of the early intermolecular contacts to
promote the recruitment of p160Gag-Pol into virions.
Additionally, we have shown that the p6 domain, which is unique to
p55Gag, contributes to the recruitment of Pol proteins into
virions (42). In the present study, we have demonstrated
that residues 5 and 7 of HIV-1 p6Gag contribute to the
incorporation of the Pol proteins within the virions. This was observed
to be cell type dependent, which correlated with the replication of the
mutant virus, and was distinct from the role of p6Gag in
virus release. These data suggest that cell-type-specific factors may
be involved in the packaging of cleaved Pol proteins during HIV-1
assembly and budding.
 |
MATERIALS AND METHODS |
DNA constructs.
The parental virus used for this study was
derived from the HXB2 clone (33). The EcoRI
site in the cellular flanking region distal to the 3' end of
the viral genome was destroyed by digestion with XbaI, which
overlaps the EcoRI site, and the DNA strands were treated with mung bean nuclease to create blunt ends and then
ligated with T4 ligase. A ClaI site was created in the
nef coding region (downstream from the env coding
region) with a mutagenic oligonucleotide:
5'-TTTTGCTATAACATCGATGGCAAGTGGTCA-3' (the
restriction site is underlined). Mutagenesis was performed according to
the manufacturer's protocol (Bio-Rad, Richmond, Calif.). The neomycin phosphotransferase gene (neoR) was PCR amplified from pLXSN
(14) with primers that incorporated ClaI and
XhoI sites at the 5' and 3' ends of neoR,
respectively. PCR was performed according to conditions described by
Perkin-Elmer with primers
5'-ATGAGGATCGATCGATATGATTGAACAAGA-3' and
5'-AACCCCAGAGCTCGAGTCAGAAGAACTCGT-3'
(restriction sites are underlined). PCR-amplified
neoR was then digested with ClaI and XhoI and cloned into the modified HXB2 construct at the
ClaI and XhoI sites of nef. The
p6Gag mutant construct (HXB2Pro) was created as previously
described (43). The env deletion (HXB2Bgl)
and p6Gag mutant with the env deletion
(HXB2ProBgl) vectors were created by removing nucleotides 6620 to
7200 of HXB2 by digestion with BglII and were religated with
T4 ligase.
Cells, DNA transfection, and infection.
COS-7 cells were
maintained in Dulbecco's modified Eagle's medium with 10% fetal
bovine serum and antibiotics and passaged upon confluence. CEM-ss,
Jurkat, and H9 cell lines were grown in RPMI 1640 with 10% fetal
bovine serum and antibiotics and maintained at a density of <1 × 106/ml. Primary blood-derived mononuclear cells (PBMC) were
activated with phytohemagglutinin and interleukin-2 prior to infection. Establishment of chronically infected Jurkat and H9 cell lines was
performed in the presence of G418. Cell culture reagents were obtained
from GIBCO/BRL.
COS-7 cells were transfected by the DEAE-dextran method. Briefly, COS-7
cells were trypsinized and seeded at 50% confluence 24 h prior to
transfection. The cells (5 × 106) were then
trypsinized, pelleted, and resuspended in 1 ml of TD buffer (25 mM
Tris-HCl [pH 7.4], 140 mM NaCl, 5 mM KCl, 0.7 mM
K2HPO4) containing 500 µg of DEAE-dextran and
5 µg of HXB2 or HXB2Pro DNA. Transfection was carried out at 37°C
for 30 min, and the cells were then washed in 5 ml of complete medium
and reseeded in T-75 flasks. Transfection of COS-7 cells with
HXB2-derived env mutants was performed as described above,
except that the cells were cotransfected with a murine leukemia virus
Env expression vector, SV-A-MLV-env (24).
Cell culture supernatants containing viral particles were harvested 3 days after transfection, precleared by centrifugation
in a Sorvall RT
6000B centrifuge at 3,000 rpm for 30 min, filtered
through a
0.2-µm-pore-size membrane, and used for infectivity
analysis.
Chronically infected cell lines were established by
exposing cells to
virus-containing cell culture supernatants and
then growing the cells
in the presence of 1.2 mg of G418/ml for
at least 2 weeks before
analysis of the cellular and viral protein
profiles.
RT assay.
Cell culture supernatants were cleared of cells
and cellular debris by centrifugation in a Sorvall MC 12V centrifuge at
14,000 rpm for 2 min. For each sample, 250 µl of culture supernatant was mixed with 125 µl of 30% polyethylene glycol-8000 with 0.5 M
NaCl at 4°C overnight. The samples were centrifuged at 2,500 rpm for
30 min (Sorvall RT 6000B), the viral pellets were dissolved in 25 µl
of RT lysis buffer (1% Triton X-100, 20 mM Tris-HCl [pH 7.5], 60 mM
KCl, 1 mM dithiothreitol, 30% glycerol), and 10 µl of each sample
was used for the RT reaction. Viral lysates were combined with 90 µl
of RT reaction cocktail {40 mM Tris-HCL (pH 7.8), 8 mM
dithiothreitol, 10 mM MgCl2, 0.05 A260 unit of poly(rA) · poly(dT)15 (Boehringer Mannheim), and 2.5 µCi of
[3H]dTTP} at 37°C for 2 h. The reaction product
was precipitated with 3 ml of chilled 10% (wt/vol) trichloroacetic
acid, with tRNA as a carrier. Incorporation of [3H]dTTP
was determined from material bound to GF/C glass microfiber filters
following five washes with chilled 5% trichloroacetic acid and
quantified with a Beckman LS 6500 scintillation counter.
Immunoblotting.
Virion-associated viral proteins were
prepared from cell culture supernatants by centrifugation at 3,000 rpm
for 30 min in a Sorvall RT 6000B centrifuge followed by filtration
through a 0.2-µm-pore-size membrane. Virus particle-containing
supernatants were concentrated by centrifugation through a 20%
sucrose cushion at 100,000 × g for 2 h in a
Sorvall Ultra80. Viral pellets were resuspended in phosphate-buffered
saline. Cell-associated viral proteins were analyzed from chronically
infected Jurkat and H9 cell lines. Cells (105) were lysed
in 1× loading dye (0.08 M Tris [pH 6.8], 2.0% sodium dodecyl
sulfate [SDS], 10% glycerol, 0.1 M dithiothreitol, 0.2% bromophenol
blue). Samples were boiled for 10 min, and proteins were separated by
SDS-polyacrylamide gel electrophoresis (PAGE). The proteins were
transferred onto two separate nitrocellulose membranes by passive
diffusion for 48 h, producing identical mirror image blots. The
membranes were probed with HIV-1-positive human serum (1:200), mouse
monoclonal antibody (MAb) against RT (1:400; BTI), or rabbit polyclonal
serum against integrase (1:400).
Radioimmunoprecipitation analysis.
Chronically infected
Jurkat and H9 cells (5 × 106) were lysed in lysis
buffer (0.15 M NaCl, 0.01 M Tris-HCl [pH 7.4], 1% Triton X-100)
containing phenylmethylsulfouyl fluoride, leupeptin, aprotinin, and
antipain. The cell lysates were precleared of nuclei by centrifugation at 1,500 × g for 5 min, and postnuclear supernatants
were then immunoprecipitated for 3 h at 4°C with p6 antiserum
(43) that had been preabsorbed with protein A-Sepharose.
Cell-associated viral proteins were analyzed by SDS-PAGE, followed by
Western blotting as described above.
Radioimmunoprecipitation of cell- and virion-associated proteins was
performed as described above, with the following modifications.
Infected H9 cells (5 × 10
6) were starved for 30 min
in cysteine-free medium containing 5%
fetal calf serum, labeled with
[
35S]cysteine (200 µCi/ml) for 12 h, and lysed in
lysis buffer. Virions
were pelleted through 20% sucrose and
resuspended in lysis buffer.
Postnuclear supernatants and the pelleted
virions were immunoprecipitated
for 3 h at 4°C with the
HIV-1-positive human serum that had been
preabsorbed with protein
A-Sepharose. Cell and virion-associated
viral proteins were analyzed by
SDS-12% PAGE and
autoradiography.
Ultrastructural studies.
Electron microscopy (EM) was
performed as previously described (43). Briefly, H9 cells
chronically infected with either HXB2Bgl or HXB2ProBgl were pelleted
and fixed for 2 h at 4°C in 0.13 M sodium phosphate containing
2.5% glutaraldehyde. The fixative was then removed, and the cells were
washed three times with 0.13 M sodium phosphate and stored overnight at
4°C. The cell pellets were minced, postfixed in 1.0% osmium
tetroxide, and washed in H2O. The cells were stained en
bloc with 2.0% aqueous uranyl acetate, dehydrated in ethanol, and
infiltrated and embedded in Spurr's plastic resin, which was
polymerized overnight at 70°C. Embedded blocks from the cell samples
were ultrathin sectioned with a Reichert-Jung Ultracut E
ultramicrotome. Ultrathin sections 60 to 80 nm thick were collected and
mounted onto copper mesh grids. The grids were poststained with
Reynold's lead citrate and examined in a Hitachi HU-12A transmission EM.
 |
RESULTS |
Mutation in HIV-1 p6Gag and replication growth
curves.
The amino acid sequence of p6Gag includes a
proline-rich amino terminus which has a high degree of
conservation among primate lentiviruses. In order to investigate the
functional role of HIV-1 p6Gag, we introduced amino acid
substitutions at two proline residues, P5R and P7Q (Fig.
1A). These mutations retain the
original amino acid sequence for the Pol open reading frame.

View larger version (30K):
[in this window]
[in a new window]
|
FIG. 1.
(A). Schematic depiction of partial HIV-1 Gag and Pol
sequences of the p6Gag mutant (HXB2Pro) and parental
construct (HXB2) used in this study. Proline residues at positions 5 and 7 of p6Gag where changed to arginine and glutamine
(boldface), respectively, without altering the Pol amino acid sequence.
(B to E) Replication growth curve of HXB2 and HXB2Pro viruses as
monitored by RT activity from cell-free supernatants. Virions were
generated from transfected COS-7 cells and used to initiate infections
in Jurkat (B), CEM (C), or H9 (D) cells or PBMC (E). PBMC were
additionally infected with a 1,000-fold-reduced concentration of the
HXB2 virus [HXB2(1/1000)], to check the relative degree of
infectivity of the HXB2Pro virus.
|
|
In order to examine the replication capacity of the p6
Gag
mutant and the parental virus (Gag
+ Pol
+
Vif
+ Vpr

Vpu

Tat
+
Rev
+ Env
+ Nef

), supernatants
derived from transfected COS-7 cells were used
to initiate infection in
Jurkat, CEM, and H9 cells and PBMC. Virus
production was monitored by
RT activity in the cultured supernatants.
In Jurkat and CEM cells, the
p6
Gag mutant HXB2Pro was competent for replication,
although it displayed
a delay in its replication compared to the
parental virus HXB2
(Fig.
1B and C). In contrast, HXB2Pro failed to
replicate in H9
cells (Fig.
1D) and PBMC (Fig.
1E). In PBMC, HXB2Pro
was at least
1,000-fold less infectious than the parental virus, HXB2
(Fig.
1E). These data demonstrate a clear cell type-dependent
replication
of this p6
Gag mutant.
Virion production by the p6Gag mutant virus in
nonpermissive H9 cells.
We next examined whether failure to
replicate in H9 cells was caused by a defect in virus release by the
p6Gag mutant virus. H9 cells expressing the parental virus
or p6Gag mutant virus lacking env were
established, and virus release was evaluated by
radioimmunoprecipitation analysis. The parental virus (HXB2Bgl) and
p6Gag mutant virus (HXB2ProBgl) expressed
comparable levels of intracellular p55Gag and p24CA in H9
cells (Fig. 2A). Examination of released
virions revealed similar quantities of p55, p24, and p17 Gag molecules in both the parental and p6Gag mutant viruses (Fig. 2B).
These data demonstrate that mutations at residues 5 and 7 of
p6Gag did not significantly influence the release of
virions from H9 cells.

View larger version (30K):
[in this window]
[in a new window]
|
FIG. 2.
Radioimmunoprecipitation of viral proteins from
uninfected H9 (Mock) cells, established H9 cell lines expressing
p6Gag mutant (HXB2ProBgl), and parental (HXB2Bgl)
constructs. The cells were metabolically labeled with
[35S]cysteine for 12 h. The proteins were
immunoprecipitated with HIV-1-positive patient serum either from cell
lysates (A) or from particles pelleted through 20% sucrose (B). The
proteins were separated by SDS-PAGE and visualized by
autoradiography.
|
|
Cell-associated p6Gag mutant viral protein
profiles.
In order to determine why infection with the
p6Gag mutant virus led to a cell type-dependent
replication, we also established chronically infected Jurkat cells. The
cell-associated viral protein composition was first examined by probing
Western blots with an HIV-1-positive human serum (Fig.
3A). A comparison of the parental virus
(HXB2Bgl) with the p6Gag mutant virus (HXB2ProBgl) in
Jurkat cell lines revealed no significant difference in the quantity or
degree of processing of Gag proteins. In nonpermissive H9 cells, the
Gag protein profiles displayed no major differences, although the
degree of Gag processing was subtly defective in the p6Gag
mutant-infected cells. There appeared to be a slight accumulation of
the Gag intermediate p41Gag and a corresponding reduction
in p24CA.

View larger version (54K):
[in this window]
[in a new window]
|
FIG. 3.
Intracellular viral protein profiles derived from
established Jurkat and H9 cell lines containing HXB2Bgl (parent) or
HXB2ProBgl (p6Gag mutant). Proteins from mock-infected and
HXB2Bgl- and HXB2ProBgl-infected cell lysates were separated by 12%
(A) or 7.5% (B) polyacrylamide gels and transferred onto
nitrocellulose membranes. The blots were reacted with either
HIV-1-positive human serum (A) or anti-RT MAb (B).
|
|
When similar blots were probed with an anti-RT MAb, again no
significant differences were apparent in Jurkat cells infected
with
HXB2Bgl or HXB2ProBgl (Fig.
3B). Comparable levels of
p160
Gag-Pol precursor, fully cleaved p66RT and p51RT,
and RT-reactive Pol
processing intermediates were apparent.
Comparable quantities
of p160
Gag-Pol precursors as well as
RT-reactive Pol processing intermediates
were also detected in HXB2Bgl-
and HXB2ProBgl-infected H9 cells
(Fig.
3B). However, the
p6
Gag mutant had significantly (approximately 5-fold)
reduced levels
of mature p66RT and p51RT compared to the parental virus
(Fig.
3B). The comparable levels of p55
Gag and
p160
Gag-Pol indicate that protein synthesis was not
compromised, but the
reduced levels of the fully mature forms of RT in
the p6
Gag mutant suggest either a defect in proteolyic
cleavage or a selective
degradation of mature RT proteins. It should be
noted that protease
function itself did not seem to be drastically
impaired, as indicated
by the existence of the Pol processing
intermediates as well as
partially cleaved p41
Gag and fully
cleaved
p24CA.
Virion-associated p6Gag mutant protein profiles.
We next examined the protein composition in cell-free virions derived
from Jurkat and H9 cell lines. When we compared the p6Gag
mutant (HXB2ProBgl) with its parent virus (HXB2Bgl) in Jurkat cell
lines, we found that the two sets of Gag, integrase, and RT proteins
were indistinguishable (Fig. 4A to C). In contrast, the protein
profiles of virions derived from p6Gag mutant virus- and
parental virus-infected H9 cells display two noticeable differences.
First, the p6Gag mutant virus-infected cells showed a
partial defect in the cleavage of the Gag protein, as evidenced by the
accumulation of p55Gag and p41Gag and a
corresponding decrease in the mature p24CA and p17MA. Although a
cleavage defect in the p6Gag mutant might suggest a defect
in viral protease activity, it should be noted that this defect was
slight and, therefore, that the protease may not be the functional
target of p6Gag activity. A more striking difference
between the parental virus and the p6Gag mutant was evident
when virion-associated proteins were stained with the anti-RT MAb (Fig.
4B) or with an anti-integrase antibody (Fig. 4C). The p6Gag mutant virions contained drastically
reduced levels of both RT and integrase compared with those of the
parental viruses.

View larger version (47K):
[in this window]
[in a new window]
|
FIG. 4.
Virion-associated-protein profiles derived from
established Jurkat and H9 cell lines containing HXB2Bgl (parent) or
HXB2ProBgl (p6Gag mutant). Virion proteins from
mock-infected and HXB2Bgl- and HXB2ProBgl-infected cells were separated
by 12% polyacrylamide gels and transferred onto nitrocellulose
membranes. The blots were reacted with either HIV-1-positive human
serum (A), anti-RT MAb (B), or anti-integrase (Int) antiserum (C).
|
|
In order to get a better estimate of the degree to which the Pol
proteins failed to be retained in the p6
Gag mutant virions,
we ran sequential twofold dilutions of the parental
viral lysates on
SDS-12% PAGE alongside the p6
Gag mutant viral lysates.
Virions derived from Jurkat cells were
stained with either the
HIV-1-positive human serum (Fig.
5A) or
the anti-RT MAb (Fig.
5B). When the overall levels of Gag proteins
were
normalized, an approximately twofold-lower level of the Pol
proteins
was observed in the p6
Gag mutant virus than in the parental
virus isolated from Jurkat
cells.

View larger version (50K):
[in this window]
[in a new window]
|
FIG. 5.
Quantitation of virion-associated protein profiles
derived from Jurkat (A and B) and H9 (C and D) cell lines. Twofold
dilutions of HXB2Bgl virion lysates (as indicated below each
corresponding lane) were run side by side with a fixed amount of
HXB2ProBgl (furthest-right lane) to compare the relative amounts of Gag
proteins and RT proteins in each sample. Virion proteins from
mock-infected and HXB2Bgl- and HXB2ProBgl-infected cells were
separated by 12% polyacrylamide gels and transferred
onto nitrocellulose membranes. The blots were reacted with either
HIV-1-positive human serum (A and C) or anti-RT MAb (B and D).
|
|
When a similar analysis was performed on the H9 cell-derived virions,
we observed an approximately 16-fold-lower level of
the Pol proteins in
the p6
Gag mutant virions than in the parental virions (Fig.
5C and D).
This defect could not be accounted for by a corresponding
reduction
in the level of the Gag-Pol precursor proteins
(p160
Gag-Pol) in the producer cell (Fig.
3B) or by an
accumulation of uncleaved
p160
Gag-Pol in the
p6
Gag mutant virions (data not shown). It should be noted
that a nonspecific,
cross-reacting band with mobility similar to that
of p66RT is
recognized by the HIV-1-positive serum used (Fig.
4 and
5).
However,
this protein band is not p66RT as it was not recognized by the
MAb against HIV-1 p66RT and
p51RT.
Intracellular p55Gag and p160Gag-Pol
association.
Since the incorporation of Pol proteins in the
virions was disrupted in the case of the p6Gag mutant
virus, we then studied the intracellular association between Gag and
Gag-Pol precursors. These experiments involved immunoprecipitation of
the Gag complex with a polyclonal antibody to p6Gag,
which did not recognize the p160Gag-Pol molecule but
did precipitate Gag-interacting molecules. The profiles of the
immunoprecipitated proteins were then examined by Western blotting
with either the HIV-1-positive serum or the RT MAb. When we compared
the p6Gag mutant with its parental virus in both
Jurkat and H9 cells, we found that similar quantities of
p160Gag-Pol and p55Gag were
coimmunoprecipitated by the p6Gag antiserum in each case
(Fig. 6A). When similar blots were
stained with the anti-RT MAb, we found that comparable levels of
Pol-reactive proteins were coimmunoprecipitated by the
p6Gag antiserum from Jurkat cells infected with the mutant
virus and from cells infected with the parental virus (Fig. 6B). In
contrast, lower levels of the mature p66RT and p51RT proteins
were coimmunoprecipitated by the p6Gag antiserum from
H9 cells infected with the p6Gag mutant virus than
from parental virus-infected H9 cells. At the same time, the levels of
the coimmunoprecipitated
p160Gag-Pol precursor and Pol intermediates were
indistinguishable (Fig. 6B).

View larger version (32K):
[in this window]
[in a new window]
|
FIG. 6.
Coimmunoprecipitation of intracellular viral complex.
Analysis of p55Gag precursor association with
p160Gag-Pol precursor- and Pol domain-containing proteins.
Proteins from mock-infected HXB2Bgl- and HXB2ProBgl-infected establish
Jurkat or H9 cell lysates were immunoprecipitated with anti-p6
antiserum as described in Materials and Methods. The anti-p6 antiserum
used specifically recognizes only p55Gag-related proteins
containing the p6 domain of Gag. The precipitated proteins were
separated on 7.5% polyacrylamide gels and transferred onto
nitrocellulose membranes. The Western blots were reacted with either
HIV-1-positive human serum (A) or anti-RT MAb (B).
|
|
Ultrastructural analysis of p6Gag mutant by
EM.
It has previously been shown that deletions of the
entire p6Gag domain result in inefficient release of
virions from the cell surface, with a corresponding accumulation of
virions at the cell surface in intermediate stages of budding (17,
43). Since the p6Gag mutant described here displayed
cell type-dependent defects, with little apparent influence on the
release of virions, it seemed useful to examine the ultrastructure of
these particles. H9 cells producing either the p6Gag mutant
or parental virions were embedded and examined by EM. Over 200 p6Gag mutant and parental virions were examined for
morphological differences (Table 1). Most
of the parental virions appeared to be mature, possessing
electron-dense cone-shaped cores (Fig. 7
and Table 1). In contrast, the majority of the p6Gag mutant
virions were immature, as evidenced by the presence of electron-dense
structural material underlying the inner leaflet of the membrane and an
absence of cone-shaped cores. There was no evidence for an increased
accumulation of p6Gag mutant budding particles at the
plasma membrane compared to that seen for the parental virus,
suggesting that release of p6Gag mutant virions was not
impaired. Thus, the p6Gag mutant phenotype described here
may be more subtle than those of previously reported p6Gag
deletion mutants (17, 43).

View larger version (116K):
[in this window]
[in a new window]
|
FIG. 7.
Ultrastructure analysis of parental and p6 mutant
virions. Viruses produced from HXB2Bgl- (A) and HXB2ProBgl-containing
(B) established H9 cells were examined by EM. Representative fields are
shown.
|
|
The EM data revealed that the majority of the p6 mutant virions
possessed immature phenotypes and a majority of the wild-type
virions
possessed mature phenotypes. However, the biochemical
data showed the
viral protease in the p6 mutant virions to be
active, albeit not at
wild-type levels (Fig.
4A). It is possible
that the immature-looking p6
mutant virions that were newly released
but did not wash away during
the EM fixation procedure may have
had a more pronounced Gag cleavage
defect because of reduced incorporation
of viral protease than did
those mutant virions analyzed by immunoblotting,
which represent older
virions. It is also possible that the Gag
proteins must be cleaved to a
certain threshold before particles
may appear fully mature. Therefore,
if not all of the p55
Gag precursors are cleaved within
a given particle, the virion may
appear to be immature by EM yet look
biochemically "mature." Alternatively,
it is possible that Gag
processing may be necessary but not sufficient
for the maturation of
HIV-1
virions.
 |
DISCUSSION |
In this study, we have examined the cell type-dependent role of
the HIV-1 p6Gag domain. Mutations introduced at residues 5 and 7 of p6Gag resulted in a lack of viral replication in
H9 cells and PBMC, whereas the mutant virus remained replication
competent in Jurkat and CEM cells despite an initial delay. Analysis of
virion-associated protein profiles demonstrated a failure of the Pol
proteins RT and integrase to be retained in the p6Gag
mutant virus particles. This defect was correlated with the cell type-dependent replication of the p6Gag mutant virus. A
previous study, using more drastic mutations in p6Gag, has
suggested a role for the p6Gag domain in the packaging of
the Pol proteins during virus assembly and budding (42).
However, the role of the p6Gag domain in Pol protein
retention could not be clearly distinguished from the domain's
proposed role in virus release (42).
During the assembly process in HIV-1, the p55Gag and
p160Gag-Pol proteins are targeted to the plasma membrane,
and proteolytic processing is initiated (38). Since
proteolytic cleavage, budding, and release of virions are dynamic and
coordinated processes, the altered timing of one of these events could
in turn affect the other steps. One interpretation of our data is that
the introduction of mutations within p6Gag results in
slower virus release. For example, if virus budding were slowed down
but proteolytic processing was not affected, the Pol domain would
become separated from the upstream Gag domain, the principal domain for
interaction between the Gag-Pol precursors and the Gag precursors. If
interaction between Gag and Gag-Pol precursors were solely dependent on
the Gag regions that are shared between the two precursors, the Pol
proteins would be excluded from the assembling p6Gag mutant
viruses if they had already been cleaved from the Gag-Pol precursor
prior to the completion of virus budding. In the present study, the
introduction of more subtle mutations in p6Gag failed to
produce a significant defect in virion release yet at the same time
caused a 16-fold reduction in the Pol proteins of mutant virions. Since
the p6Gag mutant virions studied here showed efficient
virus release, this mutation may be viewed as an intermediate between
the wild-type parental virus and the more drastic p6Gag
mutants, which show inefficient virus release as well as failure to
retain the Pol proteins. On the basis of these data, there does not
appear to be a direct link between the efficiency of virus release and
the ability to package Pol proteins in released virus particles.
The principal protein-protein interaction domains of p55Gag
and p160Gag-Pol precursor molecules are found within the
shared Gag region, including MA, CA, and NC (38). At the C
terminus of p55Gag is the p6Gag molecule, which
is not present in the p160Gag-Pol precursor. The
self-cleavage of the virus-encoded protease from the
p160Gag-Pol precursor is thought to be necessary to
initiate subsequent proteolytic cleavage events along the Gag and Pol
molecules. Since the protease is situated at the N terminus of the Pol
domain, its cleavage physically separates Gag from Pol so that the Pol
proteins lose their Gag interaction domain and no longer associate with
the virus assembly complex in the absence of other interactions. It is
possible that the p6Gag domain is involved in a
protein-protein interaction with the Pol domain. The data presented in
this report suggest that the p6Gag domain functions to
retain the Pol domain within the assembling virus after the activation
of the viral protease. This idea is also consistent with studies in
which mutations in either the RT (2, 26) or integrase
(1, 11) molecules were associated with a reduction in the
levels of Pol proteins in released mutant virions.
Since p6Gag mutations at prolines 5 and 7 were associated
with a cell type-dependent process, it appears that cell-derived
factors are involved in the retention of the Pol proteins during virus assembly. The fact that H9 cell-derived virions showed a more drastic
defect in Pol protein incorporation than did those from Jurkat cells
suggests that a cellular factor in Jurkat cells may interact with both
wild-type and p6Gag mutant molecules, whereas the analogous
factor in H9 cells may only interact with the wild-type
p6Gag molecule. Alternatively, the putative cellular factor
might be present at varying concentrations that are cell type specific. It remains to be determined whether there is indeed a factor that acts
as a molecular bridge between p6Gag and a determinant
within the Pol domain to ensure the recruitment of the Pol proteins
into virions after the initial proteolytic processing events.
Examination of the virion protein profiles supports the notion that
p6Gag may control the incorporation of Pol into virions,
although analysis of the intracellular viral proteins still leaves some
questions to be answered. Even though the synthesis of the Pr160
Gag-Pol appeared to be unimpaired in the p6Gag mutant cells
(Fig. 3), and the degree of proteolytic cleavage of Gag was not
drastically altered, a reduction in the fully cleaved forms of RT was
evident. This suggests one of two possibilities. First, in the
p6Gag mutant virus-infected cells, the final cleavage of
the mature RT molecules may be selectively suppressed. We believe this
possibility to be less likely because, in such a case, an accumulation
of p160Gag-Pol would result and be detectable in virions,
and this situation has not been observed. The second possibility is
that the mature forms of RT are indeed produced but are degraded. This
idea would have to be considered if we assume that the mature RT
molecules no longer remain part of the virus assembly complex because
of their lack of association with p6Gag and as a result
they are not protected from digestion by cellular protease(s). These
data are similar to those in previous reports in which point mutations
in the RT coding region reduced RT incorporation into virions without
influencing the intracellular level of p160Gag-Pol
(26). Selective degradation of mature RT molecules but not of p160Gag-Pol has also been reported for certain
temperature-sensitive HIV-1 RT mutants (22). In the current
study we have shown that p160Gag-Pol is not only present
intracellularly in similar quantities in the p6Gag mutant
and the parental virus but is also found in association with
p55Gag (Fig. 6). This finding argues that the introduction
of point mutations within p6Gag did not interfere with the
initial intracellular interactions between p55Gag and
p160Gag-Pol nor did it dramatically alter the structure of
p55Gag. Further studies are in progress to investigate the
mechanism by which p6Gag is involved in the incorporation
of the Pol proteins into the virion.
 |
ACKNOWLEDGMENTS |
We are grateful to Zene Matsuda, Tun-Hou Lee, and Max Essex for
several DNA constructs; to John Birnbaum for EM assistance; and to
Oliver Laeyendecker for technical assistance. The following reagent was
obtained through the AIDS Research and Reference Reagents Program,
Division of AIDS, NIAID, NIH: antiserum against HIV-1 integrase
(catalog no. 756).
M.D. was supported in part by a training grant from NIEHS
(ES07141). Support also came from a National Institutes of Health grant
(AI-35525 to X.-F.Y.).
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Molecular Microbiology and Immunology, Johns Hopkins University School of Hygiene and Public Health, 615 N. Wolfe St., Baltimore, MD 21205. Phone: (410) 955-3768. Fax: (410) 614-8263. E-mail:
xfyu{at}jhsph.edu.
 |
REFERENCES |
| 1.
|
Ansari-Lari, M. A.,
L. A. Donehower, and R. A. Gibbs.
1995.
Analysis of human immunodeficiency virus type 1 integrase mutants.
Virology
213:680[Medline].
|
| 2.
|
Ansari-Lari, M. A., and R. A. Gibbs.
1996.
Expression of human immunodeficiency virus type 1 reverse transcriptase in trans during virion release and after infection.
J. Virol.
70:3870-3875[Abstract].
|
| 3.
|
Bennett, R. P.,
T. D. Nelle, and J. W. Wills.
1993.
Functional chimeras of the Rous sarcoma virus and human immunodeficiency virus gag proteins.
J. Virol.
67:6487-6498[Abstract/Free Full Text].
|
| 4.
|
Bowzard, J. B.,
R. B. Bennett,
N. K. Krishna,
S. M. Ernst,
A. Rein, and J. W. Wills.
1998.
Importance of basic residues in nucleocapsid sequence for retrovirus Gag assembly and complementation rescue.
J. Virol.
72:9034-9044[Abstract/Free Full Text].
|
| 5.
|
Bryant, M., and L. Ratner.
1990.
Myristoylation-dependent replication and assembly of human immunodeficiency virus 1.
Proc. Natl. Acad. Sci. USA
87:523-527[Abstract/Free Full Text].
|
| 6.
|
Cosson, P.
1996.
Direct interaction between the envelope and matrix proteins of HIV-1.
EMBO J.
15:5783-5788[Medline].
|
| 7.
|
Craven, R. C.,
A. E. Leure-duPree,
R. A. Weldon, Jr., and J. W. Wills.
1995.
Genetic analysis of the major homology region of the Rous sarcoma virus Gag protein.
J. Virol.
69:4213-4227[Abstract].
|
| 8.
|
Dawson, L., and X. F. Yu.
1998.
The role of nucleocapsid of HIV-1 in virus assembly.
Virology
251:141-157[Medline].
|
| 9.
|
Dorfman, T.,
F. Mammano,
W. A. Haseltine, and H. G. Gottlinger.
1994.
Role of the matrix protein in the virion association of the human immunodeficiency virus type 1 envelope glycoprotein.
J. Virol.
68:1689-1696[Abstract/Free Full Text].
|
| 10.
|
Dubay, J. W.,
S. J. Roberts,
B. H. Hahn, and E. Hunter.
1992.
Truncation of the human immunodeficiency virus type 1 transmembrane glycoprotein cytoplasmic domain blocks virus infectivity.
J. Virol.
66:6616-6625[Abstract/Free Full Text].
|
| 11.
|
Engelman, A.,
G. Englund,
J. M. Orenstein,
M. A. Martin, and R. Craigie.
1995.
Multiple effects of mutations in human immunodeficiency virus type 1 integrase on viral replication.
J. Virol.
69:2729-2736[Abstract].
|
| 11a.
|
Franke, E. K.,
H. E. H. Yuan,
K. L. Bossolt,
S. P. Goff, and J. Luban.
1994.
Specificity and sequence requirements for interactions between various retroviral Gag proteins.
J. Virol.
68:5300-5305[Abstract/Free Full Text].
|
| 12.
|
Freed, E. O., and M. A. Martin.
1996.
Domains of the human immunodeficiency virus type 1 matrix and gp41 cytoplasmic tail required for envelope incorporation into virions.
J. Virol.
70:341-351[Abstract].
|
| 13.
|
Gamble, T. R.,
S. Yoo,
F. F. Vajdos,
U. K. von Schwedler,
D. K. Worthylake,
H. Wang,
J. P. McCutcheon,
W. I. Sundquist, and C. P. Hill.
1997.
Structure of the carboxyl-terminal dimerization domain of the HIV-1 capsid protein.
Science
278:849-853[Abstract/Free Full Text].
|
| 14.
|
Garcia, J. V., and A. D. Miller.
1991.
Serine phosphorylation-independent downregulation of cell-surface CD4 by nef.
Nature
350:508-511[Medline].
|
| 15.
|
Garnier, L.,
L. Ratner,
B. Rovinski,
S. X. Cao, and J. W. Wills.
1998.
Particle size determinants in the human immunodeficiency virus type 1 Gag protein.
J. Virol.
72:4667-4677[Abstract/Free Full Text].
|
| 16.
|
Garnier, L.,
J. W. Wills,
M. F. Verderame, and M. Sudol.
1996.
WW domains and retrovirus budding.
Nature
381:744-745[Medline]. (Letter.)
|
| 17.
|
Gottlinger, H. G.,
T. Dorfman,
J. G. Sodroski, and W. A. Haseltine.
1991.
Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release.
Proc. Natl. Acad. Sci. USA
88:3195-3199[Abstract/Free Full Text].
|
| 18.
|
Gottlinger, H. G.,
J. G. Sodroski, and W. A. Haseltine.
1989.
Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1.
Proc. Natl. Acad. Sci. USA
86:5781-5785[Abstract/Free Full Text].
|
| 19.
|
Hill, C. P.,
D. Worthylake,
D. P. Bancroft,
A. M. Christensen, and W. I. Sundquist.
1996.
Crystal structures of the trimeric human immunodeficiency virus type 1 matrix protein: implications for membrane association and assembly.
Proc. Natl. Acad. Sci. USA
93:3099-3104[Abstract/Free Full Text].
|
| 20.
|
Huang, M.,
J. M. Orenstein,
M. A. Martin, and E. O. Freed.
1995.
p6Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease.
J. Virol.
69:6810-6818[Abstract].
|
| 21.
|
Huang, M., and M. A. Martin.
1997.
Incorporation of Pr160gag-pol into virus particles requires the presence of both the major homology region and adjacent C-terminal capsid sequences within the Gag-Pol polyprotein.
J. Virol.
71:4472-4478[Abstract].
|
| 22.
|
Huang, M.,
R. Zensen,
M. Cho, and M. A. Martin.
1998.
Construction and characterization of a temperature-sensitive human immunodeficiency virus type 1 reverse transcriptase mutant.
J. Virol.
72:2047-2054[Abstract/Free Full Text].
|
| 23.
|
Kondo, E.,
F. Mammano,
E. A. Cohen, and H. G. Gottlinger.
1995.
The p6gag domain of human immunodeficiency virus type 1 is sufficient for the incorporation of Vpr into heterologous viral particles.
J. Virol.
69:2759-2764[Abstract].
|
| 24.
|
Landau, N. R.,
K. A. Page, and D. R. Littman.
1991.
Pseudotyping with human T-cell leukemia virus type I broadens the human immunodeficiency virus host range.
J. Virol.
65:162-169[Abstract/Free Full Text].
|
| 25.
|
Lu, Y. L.,
R. P. Bennett,
J. W. Wills,
R. Gorelick, and L. Ratner.
1995.
A leucine triplet repeat sequence (LXX)4 in p6gag is important for Vpr incorporation into human immunodeficiency virus type 1 particles.
J. Virol.
69:6873-6879[Abstract].
|
| 26.
|
Mak, J.,
A. Khorchid,
Q. Cao,
Y. Huang,
I. Lowy,
M. A. Parniak,
V. R. Prasad,
M. A. Wainberg, and L. Kleiman.
1997.
Effects of mutations in Pr160gag-pol upon tRNA(Lys3) and Pr160gag-pol incorporation into HIV-1.
J. Mol. Biol.
265:419-431[Medline].
|
| 27.
|
Mammano, F.,
A. Ohagen,
S. Hoglund, and H. G. Gottlinger.
1994.
Role of the major homology region of human immunodeficiency virus type 1 in virion morphogenesis.
J. Virol.
68:4927-4936[Abstract/Free Full Text].
|
| 28.
|
Morikawa, Y.,
W. Zhang,
D. J. Hockley,
M. V. Nermut, and I. M. Jones.
1998.
Detection of a trimeric human immunodeficiency virus type 1 Gag intermediate is dependent on sequences in the matrix protein, p17.
J. Virol.
72:7659-7663[Abstract/Free Full Text].
|
| 29.
|
Orlinsky, K. J.,
J. Gu,
M. Hoyt,
S. Sandmeyer, and T. M. Menees.
1996.
Mutations in the Ty3 major homology region affect multiple steps in Ty3 retrotransposition.
J. Virol.
70:3440-3448[Abstract].
|
| 30.
|
Parent, L. J.,
R. P. Bennett,
R. C. Craven,
T. D. Nelle,
N. K. Krishna,
J. B. Bowzard,
C. B. Wilson,
B. A. Puffer,
R. C. Montelaro, and J. W. Wills.
1995.
Positionally independent and exchangeable late budding functions of the Rous sarcoma virus and human immunodeficiency virus Gag proteins.
J. Virol.
69:5455-5460[Abstract].
|
| 31.
|
Paxton, W.,
R. I. Connor, and N. R. Landau.
1993.
Incorporation of Vpr into human immunodeficiency virus type 1 virions: requirement for the p6 region of gag and mutational analysis.
J. Virol.
67:7229-7237[Abstract/Free Full Text].
|
| 32.
|
Puffer, B. A.,
L. J. Parent,
J. W. Wills, and R. C. Montelaro.
1997.
Equine infectious anemia virus utilizes a YXXL motif within the late assembly domain of the Gag p9 protein.
J. Virol.
71:6541-6546[Abstract].
|
| 33.
|
Ratner, L.,
W. Haseltine,
R. Patarca,
K. J. Livak,
B. Starcich,
S. F. Josephs,
E. R. Doran,
J. A. Rafalski,
E. A. Whitehorn,
K. Baumeister, et al.
1985.
Complete nucleotide sequence of the AIDS virus, HTLV-III.
Nature
313:277-284[Medline].
|
| 34.
|
Sandefur, S.,
V. Varthakavi, and P. Spearman.
1998.
The I domain is required for efficient plasma membrane binding of human immunodeficiency virus type 1 Pr55Gag.
J. Virol.
72:2723-2732[Abstract/Free Full Text].
|
| 35.
|
Schwartz, M. D.,
R. J. Geraghty, and A. T. Panganiban.
1996.
HIV-1 particle release mediated by Vpu is distinct from that mediated by p6.
Virology
224:302-309[Medline].
|
| 36.
|
Srinivasakumar, N.,
M.-L. Hammarskjold, and D. Rekosh.
1995.
Characterization of deletion mutations in the capsid region of human immunodeficiency virus type 1 that affect particle formation and Gag-Pol precursor incorporation.
J. Virol.
69:6106-6114[Abstract].
|
| 37.
|
Strambio-de-Castillia, C., and E. Hunter.
1992.
Mutational analysis of the major homology region of Mason-Pfizer monkey virus by use of saturation mutagenesis.
J. Virol.
66:7021-7032[Abstract/Free Full Text].
|
| 38.
|
Swanstrom, R., and J. Wills.
1998.
Synthesis, assembly, and processing of viral proteins, p. 263-334.
In
J. Coffin, S. Hughes, and H. Varmus (ed.), Retroviruses. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
|
| 39.
|
Yasuda, J., and E. Hunter.
1998.
A proline-rich motif (PPPY) in the Gag polyprotein of Mason-Pfizer monkey virus plays a maturation-independent role in virion release.
J. Virol.
72:4095-4103[Abstract/Free Full Text].
|
| 40.
|
Yu, X.,
X. Yuan,
Z. Matsuda,
T. H. Lee, and M. Essex.
1992.
The matrix protein of human immunodeficiency virus type 1 is required for incorporation of viral envelope protein into mature virions.
J. Virol.
66:4966-4971[Abstract/Free Full Text].
|
| 41.
|
Yu, X.,
X. Yuan,
M. F. McLane,
T. H. Lee, and M. Essex.
1993.
Mutations in the cytoplasmic domain of human immunodeficiency virus type 1 transmembrane protein impair the incorporation of Env proteins into mature virions.
J. Virol.
67:213-221[Abstract/Free Full Text].
|
| 42.
|
Yu, X. F.,
L. Dawson,
C. J. Tian,
C. Flexner, and M. Dettenhofer.
1998.
Mutations of the human immunodeficiency virus type 1 p6Gag domain result in reduced retention of Pol proteins during virus assembly.
J. Virol.
72:3412-3417[Abstract/Free Full Text].
|
| 43.
|
Yu, X. F.,
Z. Matsuda,
Q. C. Yu,
T. H. Lee, and M. Essex.
1995.
Role of the C terminus Gag protein in human immunodeficiency virus type 1 virion assembly and maturation.
J. Gen. Virol.
76:3171-3179[Abstract/Free Full Text].
|
| 44.
|
Yuan, X.,
X. Yu,
T. H. Lee, and M. Essex.
1993.
Mutations in the N-terminal region of human immunodeficiency virus type 1 matrix protein block intracellular transport of the Gag precursor.
J. Virol.
67:6387-6394[Abstract/Free Full Text].
|
| 45.
|
Zhang, Y.,
H. Qian,
Z. Love, and E. Barklis.
1998.
Analysis of the assembly function of the human immunodeficiency virus type 1 gag protein nucleocapsid domain.
J. Virol.
72:1782-1789[Abstract/Free Full Text].
|
| 46.
|
Zhou, W.,
L. J. Parent,
J. W. Wills, and M. D. Resh.
1994.
Identification of a membrane-binding domain within the amino-terminal region of human immunodeficiency virus type 1 Gag protein which interacts with acidic phospholipids.
J. Virol.
68:2556-2569[Abstract/Free Full Text].
|
Journal of Virology, June 1999, p. 4696-4704, Vol. 73, No. 6
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Dykes, C., Demeter, L. M.
(2007). Clinical Significance of Human Immunodeficiency Virus Type 1 Replication Fitness. Clin. Microbiol. Rev.
20: 550-578
[Abstract]
[Full Text]
-
Neumann, G., Ebihara, H., Takada, A., Noda, T., Kobasa, D., Jasenosky, L. D., Watanabe, S., Kim, J. H., Feldmann, H., Kawaoka, Y.
(2005). Ebola Virus VP40 Late Domains Are Not Essential for Viral Replication in Cell Culture. J. Virol.
79: 10300-10307
[Abstract]
[Full Text]
-
Hemonnot, B., Cartier, C., Gay, B., Rebuffat, S., Bardy, M., Devaux, C., Boyer, V., Briant, L.
(2004). The Host Cell MAP Kinase ERK-2 Regulates Viral Assembly and Release by Phosphorylating the p6gag Protein of HIV-1. J. Biol. Chem.
279: 32426-32434
[Abstract]
[Full Text]
-
Bleiber, G., Peters, S., Martinez, R., Cmarko, D., Meylan, P., Telenti, A.
(2004). The central region of human immunodeficiency virus type 1 p6 protein (Gag residues S14-I31) is dispensable for the virus in vitro. J. Gen. Virol.
85: 921-927
[Abstract]
[Full Text]
-
Cen, S., Niu, M., Saadatmand, J., Guo, F., Huang, Y., Nabel, G. J., Kleiman, L.
(2004). Incorporation of Pol into Human Immunodeficiency Virus Type 1 Gag Virus-Like Particles Occurs Independently of the Upstream Gag Domain in Gag-Pol. J. Virol.
78: 1042-1049
[Abstract]
[Full Text]
-
Martin-Serrano, J., Bieniasz, P. D.
(2003). A Bipartite Late-Budding Domain in Human Immunodeficiency Virus Type 1. J. Virol.
77: 12373-12377
[Abstract]
[Full Text]
-
Maguire, M. F., Guinea, R., Griffin, P., Macmanus, S., Elston, R. C., Wolfram, J., Richards, N., Hanlon, M. H., Porter, D. J. T., Wrin, T., Parkin, N., Tisdale, M., Furfine, E., Petropoulos, C., Snowden, B. W., Kleim, J.-P.
(2002). Changes in Human Immunodeficiency Virus Type 1 Gag at Positions L449 and P453 Are Linked to I50V Protease Mutants In Vivo and Cause Reduction of Sensitivity to Amprenavir and Improved Viral Fitness In Vitro. J. Virol.
76: 7398-7406
[Abstract]
[Full Text]
-
Freed, E. O.
(2002). Viral Late Domains. J. Virol.
76: 4679-4687
[Full Text]
-
Muller, B., Patschinsky, T., Krausslich, H.-G.
(2002). The Late-Domain-Containing Protein p6 Is the Predominant Phosphoprotein of Human Immunodeficiency Virus Type 1 Particles. J. Virol.
76: 1015-1024
[Abstract]
[Full Text]
-
Demirov, D. G., Orenstein, J. M., Freed, E. O.
(2002). The Late Domain of Human Immunodeficiency Virus Type 1 p6 Promotes Virus Release in a Cell Type-Dependent Manner. J. Virol.
76: 105-117
[Abstract]
[Full Text]
-
Guan, Y., Diallo, K., Detorio, M., Whitney, J. B., Liang, C., Wainberg, M. A.
(2001). Partial Restoration of Replication of Simian Immunodeficiency Virus by Point Mutations in either the Dimerization Initiation Site (DIS) or Gag Region after Deletion Mutagenesis within the DIS. J. Virol.
75: 11920-11923
[Abstract]
[Full Text]
-
Peters, S., Munoz, M., Yerly, S., Sanchez-Merino, V., Lopez-Galindez, C., Perrin, L., Larder, B., Cmarko, D., Fakan, S., Meylan, P., Telenti, A.
(2001). Resistance to Nucleoside Analog Reverse Transcriptase Inhibitors Mediated by Human Immunodeficiency Virus Type 1 p6 Protein. J. Virol.
75: 9644-9653
[Abstract]
[Full Text]
-
Reichert, M., Winnicka, A., Willems, L., Kettmann, R., Cantor, G. H.
(2001). Role of the Proline-Rich Motif of Bovine Leukemia Virus Transmembrane Protein gp30 in Viral Load and Pathogenicity in Sheep. J. Virol.
75: 8082-8089
[Abstract]
[Full Text]
-
VerPlank, L., Bouamr, F., LaGrassa, T. J., Agresta, B., Kikonyogo, A., Leis, J., Carter, C. A.
(2001). Tsg101, a homologue of ubiquitin-conjugating (E2) enzymes, binds the L domain in HIV type 1 Pr55Gag. Proc. Natl. Acad. Sci. USA
10.1073/pnas.131059198v1
[Abstract]
[Full Text]
-
VerPlank, L., Bouamr, F., LaGrassa, T. J., Agresta, B., Kikonyogo, A., Leis, J., Carter, C. A.
(2001). Tsg101, a homologue of ubiquitin-conjugating (E2) enzymes, binds the L domain in HIV type 1 Pr55Gag. Proc. Natl. Acad. Sci. USA
98: 7724-7729
[Abstract]
[Full Text]